LEAF Rwanda

L.E.A.F. Rwanda Ltd (LEAF Rwanda) is a Kigali-based biotechnology company and a wholly owned subsidiary of the US-based L.E.A.F. Pharmaceuticals LLC. Established in 2017, the company's mission is to establish Rwanda as a premier hub for biotechnology research, development, and pharmaceutical manufacturing in Africa. LEAF Rwanda is focused on developing and commercializing high-quality, affordable anticancer medicines to address critical healthcare gaps on the African continent. Its lead program, LEAF-1404, is a complex generic version of pegylated liposomal doxorubicin (Caelyx/Doxil) intended for the treatment of ovarian cancer, breast cancer, and Kaposi Sarcoma. Through partnerships with its parent company and global contract manufacturing organizations, LEAF Rwanda aims to facilitate advanced skills transfer and build cGMP-compliant manufacturing capabilities in East Africa.